Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Atezolizumab + Talimogene laherparepvec|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Atezolizumab||Tecentriq||RG7446|MPDL3280A||Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 86||Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in PD-L1 positive advanced or metastatic urothelial carcinoma not eligible for cisplatin-containing chemotherapy, in advanced or metastatic urothelial carcinoma not eligible for chemotherapy or progressed on platinum-based chemotherapy, in metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, as first-line therapy in metastatic NSCLC with high PD-L1 expression (TC>=50% or IC>=10%) and without EGFR or ALK alterations, for adjuvant treatment in patients with PD-L1-positive (>=1% tumor cell expression) NSCLC, in combination with bevacizumab, paclitaxel, and carboplatin as first-line therapy for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound and carboplatin in metastatic non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound in advanced or metastatic triple-negative breast cancer expressing PD-L1, in combination with carboplatin and etoposide in extensive-stage small cell lung cancer, in combination with bevacizumab in hepatocellular carcinoma without prior systemic therapy, and in combination with cobimetinib and vemurafenib in BRAF V600-mutated melanoma (FDA.gov).|
|Talimogene laherparepvec||Imlygic||OncoVEX GM-CSF|T-VEC||Imlygic (talimogene laherparepvec) is a GM-CSF expressing herpes simplex type-1 virus (HSV-1) that selectively infects and lyses tumor cells, and potentially induces a cytotoxic immune response against tumor cells (PMID: 25777572). Imlygic (talimogene laherparepvec) is FDA approved for use in patients with recurrent melanoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03256344||Phase I||Atezolizumab + Talimogene laherparepvec||Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases||Completed||USA | ESP | DEU | BEL||2|
|NCT03802604||Phase I||Atezolizumab + Talimogene laherparepvec||Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer (PROMETEO)||Active, not recruiting||ESP||0|